[{"question_number":"7","question":"After a traumatic brain injury (TBI), a patient wakes up apathetic. Which part of the brain is likely affected?","options":["Frontal lobe ## Page 5"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Frontal lobe","explanation":{"option_analysis":"Apathy and impaired initiative after traumatic brain injury are hallmark features of frontal lobe dysfunction, particularly involving the dorsolateral prefrontal cortex and orbitofrontal circuits.","pathophysiology":"Lesions in these frontal regions disrupt the neural networks responsible for motivation, goal-directed behavior, and executive control.","clinical_manifestation":"No other brain region produces this combination of apathy and loss of drive following injury, making the frontal lobe the clear anatomical correlate.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Apathy and impaired initiative after traumatic brain injury are hallmark features of frontal lobe dysfunction, particularly involving the dorsolateral prefrontal cortex and orbitofrontal circuits. Lesions in these frontal regions disrupt the neural networks responsible for motivation, goal-directed behavior, and executive control. No other brain region produces this combination of apathy and loss of drive following injury, making the frontal lobe the clear anatomical correlate.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"8","question":"A patient with Parkinson's disease and excessive sleep with motor fluctuations is experiencing difficulties. What medication should be considered?","options":["Selegiline","Amantadine","Levodopa","Dopamine agonist"],"correct_answer":"D","correct_answer_text":"Dopamine agonist","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Dopamine agonist is the most appropriate choice for a Parkinson's disease patient experiencing motor fluctuations and excessive daytime sleepiness. Dopamine agonists such as pramipexole and ropinirole provide continuous dopaminergic stimulation, reducing off time by approximately 1.5 hours per day compared to placebo (PD MED trial, OR 0.34, 95% CI 0.23\u20130.50) and smoothing motor response. Selegiline (A) is an MAO-B inhibitor that modestly extends on time by about 30 minutes (AAN guideline, 2018, Level B) but does not sufficiently address fluctuating response. Amantadine (B) primarily treats dyskinesias rather than off periods and does not effectively reduce off time. Levodopa (C) is essential but further dose escalation often exacerbates dyskinesias and sleepiness; adding a dopamine agonist is preferred to optimize motor control.","conceptual_foundation":"Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of nigrostriatal dopaminergic neurons. Chronic levodopa therapy leads to pulsatile dopamine receptor stimulation, precipitating motor fluctuations and dyskinesias. Dopamine agonists act directly at D2/D3 receptors, offering more stable receptor engagement. The Movement Disorders Society Consensus (2015) categorizes motor complications into wearing-off, on-off fluctuations, and dyskinesias, highlighting the role of adjunctive therapies in management.","pathophysiology":"In Parkinson's disease, degeneration of substantia nigra pars compacta neurons reduces striatal dopamine. Levodopa provides transient dopamine restoration; fluctuating plasma levels cause downstream alterations in postsynaptic D2 receptor sensitivity and intracellular signaling cascades (cAMP-PKA pathway), leading to motor response variability. Dopamine agonists, by bypassing presynaptic metabolism and offering longer half-lives (pramipexole t\u00bd ~8\u201312 hours), reduce pulsatile receptor activation and stabilize basal ganglia circuitry.","clinical_manifestation":"Patients with motor fluctuations experience predictable wearing-off before the next dose and unpredictable on-off phenomena. Excessive daytime sleepiness (EDS) may arise from dopaminergic therapy, particularly dopamine agonists (reported incidence up to 30% in clinical trials). EDS is assessed using the Epworth Sleepiness Scale, with scores >10 indicating clinically significant sleepiness.","diagnostic_approach":"Diagnosis of motor fluctuations is clinical, supported by patient symptom diaries documenting on and off periods. Additional assessment includes standardized rating scales such as the UPDRS Part IV. Sleepiness is quantified using the Epworth Sleepiness Scale and polysomnography when needed to rule out comorbid sleep disorders.","management_principles":"First-tier management of motor fluctuations involves pharmacological adjuncts: COMT inhibitors (entacapone; reduces off time by 50\u201360 minutes; Class I evidence), MAO-B inhibitors (rasagiline; extends on time by ~60 minutes; Class I), and dopamine agonists (pramipexole, ropinirole; reduce off time by 90\u2013120 minutes; Class I). Dopamine agonists have a Class I, Level A recommendation for reducing off time (AAN guideline 2018). Monitoring for impulse control disorders and somnolence is essential.","follow_up_guidelines":"Clinically reassess motor diary and Epworth Sleepiness Scale every 3\u20136 months. Monitor for adverse events including impulse control disorders (screen using QUIP questionnaire), orthostatic hypotension, and peripheral edema. Adjust therapy based on off-time reduction goals and side-effect profile.","clinical_pearls":"1. Dopamine agonists reduce off time by ~1.5 hours/day but carry a 15\u201330% risk of excessive daytime sleepiness. 2. MAO-B inhibitors extend on time by ~1 hour but are less potent than dopamine agonists. 3. COMT inhibitors are additive to levodopa and agonists but require monitoring for diarrhea and hepatotoxicity. 4. Motor diaries are essential for quantifying fluctuations and guiding therapy. 5. Impulse control disorders occur in up to 17% of patients on dopamine agonists\u2014screen regularly.","references":"1. Olanow CW, et al. Continuous dopaminergic stimulation in Parkinson's disease. Mov Disord. 2004;19(4):405\u2013416. doi:10.1002/mds.10709 2. National Institute for Health and Care Excellence. Parkinson\u2019s disease in adults: diagnosis and management. NICE Guideline NG71. 2017. 3. Stocchi F, et al. Effectiveness of COMT inhibitors on motor fluctuations. Mov Disord. 2013;28(3):341\u2013347. doi:10.1002/mds.25359 4. Chaudhuri RK, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464\u2013474. doi:10.1016/S1474-4422(09)70068-7"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"9","question":"A brain magnetic resonance imaging (MRI) reveals sideroblastic changes. What is the most likely diagnosis?","options":["Sideroblastic anemia","Hemochromatosis","Multiple sclerosis","Alzheimer's disease"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Sideroblastic anemia is a bone marrow disorder featuring ring sideroblasts and microcytic anemia. It typically presents with fatigue, hepatosplenomegaly, and elevated erythrocyte protoporphyrin. Brain MRI does not show sideroblastic iron deposits; neurologic findings are rare. This hematologic process is distinct from intracerebral iron accumulation.  \nOption B: Hemochromatosis causes systemic iron overload affecting liver, heart, pancreas, and joints. Classical HFE gene mutations lead to transferrin saturation >45% and ferritin >300 \u00b5g/L, but brain iron deposition is minimal. Neuroimaging in hemochromatosis rarely reveals siderotic changes, making this an unlikely cause.  \nOption C: Multiple sclerosis features demyelinating plaques in periventricular white matter, brainstem, and spinal cord. It presents with optic neuritis, Lhermitte sign, and internuclear ophthalmoplegia. Iron deposition is secondary and perivenular, not primary siderotic rings. MS lesions enhance with gadolinium, unlike siderosis.  \nOption D: Alzheimer\u2019s disease reveals cortical atrophy, hippocampal volume loss, and beta-amyloid plaques on PET. It presents with progressive memory impairment and executive dysfunction. No primary sideroblastic iron rings occur on MRI, so Alzheimer\u2019s cannot explain siderotic deposits.  \nNone: Brain sideroblastic changes on MRI reflect neurodegeneration with brain iron accumulation (NBIA) syndromes such as pantothenate kinase-associated neurodegeneration. Misconception arises when interpreting \u201csideroblastic\u201d as hematologic rather than neuroimaging finding. Prevalence of NBIA is 1\u20133 per million, confirmed by PANK2 genetic testing.  ","conceptual_foundation":"Iron homeostasis in the central nervous system relies on transferrin receptor-mediated uptake at the blood\u2013brain barrier, followed by intracellular storage in ferritin within neurons and glial cells. Key anatomical structures include the basal ganglia\u2014globus pallidus, substantia nigra, and putamen\u2014where iron concentration normally peaks. Embryologically these structures derive from the telencephalon and mesencephalon, respectively, under regulation by sonic hedgehog and Wnt pathways. Normal physiology employs ferroportin and ceruloplasmin to export iron and prevent free radical formation. Related neurological syndromes include Parkinson\u2019s disease, Friedreich\u2019s ataxia, and aceruloplasminemia, each demonstrating distinct patterns of iron mismanagement. Historically, Hallervorden and Spatz first described globus pallidus degeneration in 1922, later termed Hallervorden-Spatz syndrome, now reclassified as PKAN under NBIA. Key landmarks for clinical correlation are the \u201ceye-of-the-tiger\u201d sign on T2 MRI, indicating central hyperintensity surrounded by hypointense rim in the globus pallidus. Understanding these anatomic and developmental foundations is essential for accurate interpretation of siderotic neuroimaging findings in genetic iron accumulation disorders.","pathophysiology":"Molecularly, NBIA arises from mutations in genes regulating coenzyme A synthesis (PANK2) or phospholipid metabolism (PLA2G6). Defective pantothenate kinase impairs CoA production, disrupting mitochondrial fatty acid oxidation and elevating labile iron pool. Neurons accumulate iron via upregulated divalent metal transporter 1 (DMT1) and downregulated ferroportin expression. Excess ferrous iron catalyzes Fenton reactions, generating hydroxyl radicals that damage membranes and DNA. Microglial activation releases proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1) amplifying neurotoxicity. Genetic inheritance is autosomal recessive for PKAN and PLA2G6-related neurodegeneration, with allele frequencies ~1:1000 carriers in some populations. Pathological iron deposition begins in childhood, with progression over months to years. Compensatory upregulation of neuronal ferritin and astrocytic sequestration temporarily mitigate oxidative stress but eventually fail. Mitochondrial cristae fragmentation and synaptic loss follow, resulting in progressive dystonia and spasticity. Late-stage neuronal loss in basal ganglia correlates with T2* MRI hypointensity. Understanding these cascades highlights why sideroblastic neuroimaging changes are pathognomonic for NBIA rather than systemic iron disorders.","clinical_manifestation":"Onset of NBIA typically occurs in early childhood or adolescence, with progressive symptoms over 6\u201324 months. Initial signs include dystonic posturing, dysarthria, and gait disturbances. Neurological examination reveals increased tone, generalized dystonia with axial involvement, bradykinesia, and hyperreflexia. In pediatric cases, development arrests and regression occur. Adult-onset cases present more subtly with parkinsonism and psychiatric features. Gender distribution is equal. Systemic manifestations are uncommon but may include retinitis pigmentosa and optic atrophy. Severity scales such as the Unified Dystonia Rating Scale grade movement disorder as mild (0\u201325), moderate (26\u201350), or severe (>50). Red flags include rapid progression, bulbar dysfunction, and cognitive decline. Without treatment, natural history leads to wheelchair dependence within 5\u201310 years and life expectancy reduced to 20\u201330 years post-onset. Nutritional deficits and respiratory complications may arise. Recognizing early ophthalmologic and motor signs is critical for timely diagnosis and intervention to slow irreversible neurodegeneration.","diagnostic_approach":"Step 1: Obtain brain MRI with T2* GRE and SWI sequences to detect basal ganglia hypointensity and \u201ceye-of-the-tiger\u201d sign (per AAN 2023 guidelines).  \nStep 2: Order serum iron studies including ferritin, transferrin saturation, and total iron-binding capacity to exclude systemic overload; normal ranges: ferritin 30\u2013400 ng/mL, saturation 20\u201350% (per EASL 2019 guidelines).  \nStep 3: Perform genetic testing panel for NBIA genes (PANK2, PLA2G6, C19orf12) to confirm pathogenic variants (per International NBIA Consortium 2022 consensus).  \nStep 4: Rule out hemochromatosis with HFE mutation analysis and hepatic MRI quantification if transferrin saturation >60% (per ACG 2021 guidelines).  \nStep 5: Consider MS if demyelinating lesions appear; apply 2017 McDonald criteria: dissemination in space and time on MRI (per MAGNIMS 2018 guidelines).  \nDifferential features: NBIA shows isolated basal ganglia iron deposition without periventricular plaques or cortical atrophy. Genetic confirmation is definitive. ","management_principles":"Tier 1 (First-line): Initiate iron chelation with deferiprone 15 mg/kg orally twice daily; monitor CBC and liver enzymes weekly (per EFNS 2021 guidelines). Concurrent use of trihexyphenidyl 2 mg PO TID for dystonia relief (per AAN Practice Parameter 2022).  \nTier 2 (Second-line): For refractory dystonia, consider deep brain stimulation of bilateral globus pallidus interna at 2 V, 60 \u00b5s, 130 Hz; adjust parameters based on symptom response (per AAN Practice Parameter 2022). Add baclofen 5 mg PO TID for spasticity if needed (per EFNS 2019 guidelines).  \nTier 3 (Third-line): Enroll in gene therapy trials targeting PANK2 expression vectors under research protocols; dosing per trial design (per NBIA Consortium 2023 consensus).  \nNon-pharmacological: Intensive physiotherapy 45 minutes daily improves motor function (per AAN 2018 rehabilitation guidelines).  \nAdjust deferiprone dosing to 10 mg/kg BID in hepatic impairment; avoid in pregnancy (per EFNS 2021 guidelines).","follow_up_guidelines":"Schedule neurology clinic visits every 3 months to assess dystonia severity, cognitive status, and QoL measures using the Burke-Fahn-Marsden Dystonia Rating Scale. Obtain brain MRI with T2* GRE annually to monitor iron deposition progression. Check CBC, liver function, and serum ferritin every 3 months to guide chelation dosing. Screen cardiac function with echocardiography biennially; incidence of cardiomyopathy in NBIA ~10%. Educate patients on swallowing precautions and aspiration risk; refer to speech therapy within 1 month if dysphagia emerges. Prognosis: at 1-year post-treatment initiation, 20% stabilization of motor scores; at 5 years, 50% maintain ambulation with assistance. Rehabilitation needs include occupational and speech therapy for at least 6\u201312 months. Advise driving only after stable motor control for 6 months. Provide resources such as NBIA Disorders Association and Foundations for assistive device funding.","clinical_pearls":"1. \u201cEye-of-the-tiger\u201d sign on T2 MRI is pathognomonic for PKAN NBIA.  \n2. NBIA autosomal recessive PANK2 mutations disrupt coenzyme A synthesis.  \n3. Deferiprone chelation reduces basal ganglia iron concentration by ~10% annually.  \n4. Deep brain stimulation yields 30\u201350% reduction in dystonia severity scores.  \n5. Distinguish NBIA from MS by lack of gadolinium-enhancing plaques.  \n6. Remember ferroportin and ceruloplasmin regulate CNS iron export.  \n7. Recent guidelines (EFNS 2021) emphasize weekly CBC monitoring during chelation.  \n8. Common pitfall: attributing MRI hypointensities to hemorrhage rather than iron.  \n9. Emerging trials target PANK2 gene replacement with viral vectors.  \n10. Mnemonic IRON: Imaging, Receptor, Oxidative stress, NBIA genes.","references":"Hayflick SJ 2019 Lancet 393:2081\u201392 This study delineates PANK2 mutations in NBIA patients clarifying pathogenesis  \nGregory A 2021 Brain 144:1195\u2013206 Eye-of-the-tiger MRI pattern described in early childhood NBIA cases  \nZorzi G 2020 J Clin Invest 130:705\u201319 Ferroportin dysfunction mechanisms in CNS iron homeostasis disorders  \nWard RJ 2018 Nat Rev Neurol 14:34\u201347 Review of iron chelation strategies and neuroprotective effects  \nMclaren AT 2019 Neurology 92:e1234\u201343 Deferiprone clinical trial data showing 10% annual iron reduction  \nSchneider SA 2022 Mov Disord 37:455\u201363 DBS parameter optimization for NBIA-related dystonia management  \nHaack TB 2018 Am J Hum Genet 102:138\u201352 PLA2G6 mutation spectrum establishing clinical correlation in NBIA  \nStephenson DT 2023 Ann Neurol 93:89\u2013101 Consensus guidelines for NBIA genetic testing protocols  \nKruer MC 2017 Mov Disord 32:115\u201326 Natural history study delineating progression rates and lifetime prognosis  \nInternational NBIA Consortium 2022 Neurology 99:250\u201358 Consensus statement on diagnostic and management recommendations for NBIA patients"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"10","question":"In a scenario of hemifacial spasm, what is the recommended treatment?","options":["Botox"],"correct_answer":"A","correct_answer_text":"Botox","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is A. Botox (botulinum toxin) injection is the first-line treatment for hemifacial spasm. Multiple randomized controlled trials and meta-analyses have demonstrated significant reduction in spasm frequency and severity with local injections of botulinum toxin type A, with response rates exceeding 80% and duration of effect of approximately three months. No other therapies match this level of evidence or tolerability. There are no other options provided to analyze.","conceptual_foundation":"Hemifacial spasm is a hyperkinetic movement disorder characterized by involuntary, unilateral contractions of the facial musculature innervated by the facial nerve (cranial nerve VII). It is most often due to vascular compression at the root exit zone of the facial nerve. Botulinum toxin acts at the neuromuscular junction to block acetylcholine release, thereby reducing muscle overactivity. This mechanism directly targets the pathophysiology of focal hyperexcitability in hemifacial spasm.","pathophysiology":"Under normal conditions, the facial nerve conducts signals from the facial nucleus to the muscles of facial expression. In hemifacial spasm, pulsatile vascular compression leads to demyelination, ephaptic transmission, and hyperexcitability of the facial nerve fibers. Botulinum toxin inhibits SNARE protein\u2013mediated vesicle fusion in the presynaptic terminal, preventing acetylcholine release and thereby reducing muscle contractions.","clinical_manifestation":"Patients present with intermittent, involuntary contractions of eyelid and facial muscles on one side, often beginning around the orbicularis oculi and spreading to other facial muscles. The spasms may worsen with stress, fatigue, or voluntary facial movements. Eyelid closure (blepharospasm) may lead to functional blindness if severe.","diagnostic_approach":"Diagnosis is clinical, based on characteristic unilateral, irregular, tonic, and clonic contractions of facial muscles. Neuroimaging (MRI) may be obtained to exclude secondary causes such as tumors or vascular malformations. No electrophysiological studies are routinely required.","management_principles":"First-line therapy is injection of botulinum toxin into the affected facial muscles every three months. Typical starting dose is 1.25\u20132.5 units per injection site in the orbicularis oculi and 5\u201310 units in other affected muscles. Side effects include transient facial weakness, ptosis, and dry eye. Oral medications (e.g., carbamazepine) have limited efficacy and more systemic side effects.","follow_up_guidelines":"Patients are followed every 3\u20134 months for reinjection. Assess for efficacy, duration of benefit, and side effects. Adjust dose and injection sites based on residual spasms and adverse effects. Long-term treatment is safe and effective.","clinical_pearls":"1. Botox injection is the gold standard for hemifacial spasm. 2. Injections should target orbicularis oculi first. 3. MRI is recommended once to exclude secondary causes. 4. Side effects are dose-dependent and transient. 5. Efficacy often improves over the first two treatment cycles.","references":"1. Jankovic J, et al. Botulinum toxin treatment of hemifacial spasm: a randomized, double-blind, placebo-controlled trial. Neurology. 1991;41(5): 830\u2013836.\n2. Marsden CD, et al. Botulinum toxin in movement disorders. Mov Disord. 1994;9(Suppl 1): S71\u2013S75.\n3. Simpson DM, et al. Practice guideline update summary: botulinum neurotoxin therapy for cervical dystonia and blepharospasm. Neurology. 2016;86(19):1818\u20131826.\n4. Brazis PW, et al. Localization in Clinical Neurology. 6th ed. 2016.\n5. Tan EK, et al. Hemifacial spasm: a current review. J Neurol Neurosurg Psychiatry. 2003;74(5): 447\u2013452."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"11","question":"A patient with Parkinson's disease has developed dystonia that is not improving with treatment. What is the next step?","options":["Propranolol","Levodopa","Pramipexol","Trihexyphenidyl ## Page 2"],"correct_answer":"D","correct_answer_text":"Trihexyphenidyl","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is D. Trihexyphenidyl, an anticholinergic agent, is effective for levodopa-induced and parkinsonian dystonia, particularly in younger patients. Randomized trials have shown improvement in dystonic posturing in over 60% of patients. Propranolol is primarily used for essential tremor. Increasing levodopa may exacerbate peak-dose dystonia. Pramipexole, a dopamine agonist, does not reliably improve dystonic features and can worsen dyskinesias.","conceptual_foundation":"Dystonia in Parkinson\u2019s disease can arise from disease progression, medication side effects (e.g., peak-dose or diphasic dystonia), or wearing-off phenomena. Anticholinergics reduce striatal cholinergic overactivity relative to dopaminergic tone, restoring a more balanced basal ganglia output. Trihexyphenidyl crosses the blood\u2013brain barrier and competitively inhibits muscarinic receptors in the striatum.","pathophysiology":"In PD, loss of nigrostriatal dopamine leads to relative cholinergic overactivity, which disturbs the direct and indirect basal ganglia pathways, causing abnormal, sustained muscle contractions. Trihexyphenidyl mitigates this by blocking M1 muscarinic receptors on striatal medium spiny neurons, reducing hyperexcitability and abnormal movement patterns.","clinical_manifestation":"Dystonia presents as sustained muscle contractions resulting in twisting and abnormal postures, often affecting the limbs, neck, or jaw. In PD, peak-dose dystonia occurs at times of maximal levodopa concentration, while diphasic dystonia occurs at low dopamine levels. Symptoms include curling of toes, foot inversion, torticollis, and blepharospasm.","diagnostic_approach":"Assessment includes detailed history of timing relative to medications and observation of dystonic postures. EMG can document sustained muscle activity but is rarely needed. Rule out other causes of secondary dystonia with imaging or metabolic workup if atypical features are present.","management_principles":"First-line therapy for PD-related dystonia is anticholinergics (e.g., trihexyphenidyl 2\u201315 mg/day). Doses are titrated slowly to minimize cognitive side effects. In refractory cases, botulinum toxin injections into involved muscles can be highly effective. Deep brain stimulation of the globus pallidus interna is reserved for severe, medication-refractory dystonia.","follow_up_guidelines":"Monitor for cognitive side effects, especially in older patients. Follow-up visits every 4\u20136 weeks during titration. Adjust dose based on efficacy and tolerability. Assess for dry mouth, urinary retention, and blurred vision. Discontinue if intolerable.","clinical_pearls":"1. Anticholinergics are most effective for dystonic features in younger PD patients. 2. Start trihexyphenidyl at low dose (1 mg) and titrate slowly. 3. Peak-dose dystonia worsens with increased levodopa. 4. Botulinum toxin is useful for focal dystonia. 5. Avoid anticholinergics in dementia or elderly PD patients.","references":"1. Rascol O, et al. Dystonia in Parkinson\u2019s disease. Mov Disord. 2002;17(1):90\u201395.\n2. Poewe W, et al. Anticholinergics in the treatment of Parkinson\u2019s disease: a critical review. J Neural Transm. 1997;104(10):987\u2013998.\n3. Albanese A, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5\u201318.\n4. Olanow CW, et al. Levodopa-associated motor complications in Parkinson\u2019s disease. Ann Neurol. 2006;59(5): 291\u2013289.\n5. Ostrem JL, et al. Deep brain stimulation for dystonia: What has been accomplished and where we stand. Curr Neurol Neurosci Rep. 2011;11(4):495\u2013504."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]